At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, engages in developing new molecules to treat mental health conditions in North America. The company's lead asset, RE104, a proprietary, novel, and serotonergic psychedelic compound. It is also developing the RE200 series, which includes preclinical compounds with enhanced receptor selectivity to address additional therapeutic applications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.